INmune Bio, Inc.
XPro1595
Alzheimer's disease
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for XPro1595 in Alzheimer's disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“Phase 3 Registrational Evaluation: The Phase 3 portion is expected to evaluate definitive clinical outcomes, including the Clinical Dementia Rating Scale–Sum of Boxes (CDR-SB), which the FDA has raised no objections to using as the sole pri”